Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Buy
54
SCPH Quote, Financials, Valuation and Earnings
Last price:
$3.32
Seasonality move
:
-3.25%
Day range:
$3.30 - $3.47
52-week range:
$1.94 - $5.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.02x
P/B ratio:
10.87x
Volume:
272K
Avg. volume:
377.5K
1-year change:
-0.99%
Market cap:
$185M
Revenue:
$36.3M
EPS (TTM):
-$1.91
Analysts' Opinion
-
Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.17, scPharmaceuticals has an estimated upside of 332.72% from its current price of $3.51.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $3.51.
Fair Value
-
According to the consensus of 4 analysts, scPharmaceuticals has 332.72% upside to fair value with a price target of $15.17 per share.
SCPH vs. S&P 500
-
Over the past 5 trading days, scPharmaceuticals has overperformed the S&P 500 by 24.13% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
scPharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
scPharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter scPharmaceuticals reported revenues of $11.8M.
Earnings Growth
-
scPharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter scPharmaceuticals reported earnings per share of -$0.37.
Enterprise value:
178.5M
EV / Invested capital:
3.89x
Price / LTM sales:
4.02x
EV / EBIT:
--
EV / Revenue:
4.25x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-2.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$28.9M
Return On Assets:
-97.1%
Net Income Margin (TTM):
-216.24%
Return On Equity:
-624.21%
Return On Invested Capital:
-148.54%
Operating Margin:
-151.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $17.6M | $42M | $6.1M | $11.8M | |
| Gross Profit | $1.5M | $12.6M | $28.9M | $4.3M | $8.3M | |
| Operating Income | -$40.5M | -$59.7M | -$66.7M | -$15.9M | -$17.8M | |
| EBITDA | -$35.1M | -$49.3M | -$83.8M | -$12M | -$18.3M | |
| Diluted EPS | -$1.32 | -$1.48 | -$1.91 | -$0.36 | -$0.37 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $99.1M | $68.2M | $126.7M | $76.5M | $89.4M | |
| Total Assets | $100.3M | $68.9M | $127.4M | $78.5M | $91M | |
| Current Liabilities | $9.6M | $14.2M | $7.7M | $12.3M | $16.3M | |
| Total Liabilities | $24.8M | $19.5M | $51.6M | $53.9M | $96.1M | |
| Total Equity | $75.5M | $49.4M | $75.8M | $24.6M | -$5.1M | |
| Total Debt | -- | -- | $37.3M | $39.4M | $51.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$43.7M | -$60.5M | -$70M | -$17.7M | -$17.1M | |
| Cash From Investing | -$26.1M | $42.3M | -$20K | $29.3M | -- | |
| Cash From Financing | $93.4M | $1.2M | $69.1M | $15K | -$972K | |
| Free Cash Flow | -$43.7M | -$60.5M | -$70M | -$17.7M | -$17.1M | |
SCPH
Sector
Market Cap
$185M
$34.8M
Price % of 52-Week High
62.04%
44.26%
Dividend Yield
0%
0%
Shareholder Yield
-34.62%
-0.59%
1-Year Price Total Return
-0.99%
-42.23%
Beta (5-Year)
0.170
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.04
200-day SMA
Sell
Level
$3.66
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$2.70
Relative Strength Index (RSI14)
Buy
Level
61.58
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-4.661
50-day SMA
Buy
Level
$2.67
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.6703)
Sell
CA Score
(Annual)
Level (-4.9339)
Sell
Beneish M-Score
(Annual)
Level (-0.4982)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.1058)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Stock Forecast FAQ
In the current month, SCPH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SCPH average analyst price target in the past 3 months is $15.17.
-
Where Will scPharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that scPharmaceuticals share price will rise to $15.17 per share over the next 12 months.
-
What Do Analysts Say About scPharmaceuticals?
Analysts are divided on their view about scPharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that scPharmaceuticals is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is scPharmaceuticals's Price Target?
The price target for scPharmaceuticals over the next 1-year time period is forecast to be $15.17 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SCPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for scPharmaceuticals is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SCPH?
You can purchase shares of scPharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase scPharmaceuticals shares.
-
What Is The scPharmaceuticals Share Price Today?
scPharmaceuticals was last trading at $3.32 per share. This represents the most recent stock quote for scPharmaceuticals. Yesterday, scPharmaceuticals closed at $3.51 per share.
-
How To Buy scPharmaceuticals Stock Online?
In order to purchase scPharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cognizant Stock Be In 5 Years?
Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…
NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
66
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
51
AAP alert for May 24
Advance Auto Parts [AAP] is down 0.98% over the past day.
Buy
67
IONQ alert for May 23
IonQ [IONQ] is down 0.48% over the past day.
Buy
75
URBN alert for May 23
Urban Outfitters [URBN] is down 1.24% over the past day.
